Treatment with first- or second-generation epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) is effective for patients with non-small cell lung cancer (NSCLC) who harbor a sensitizing EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.